Pamela Stephenson
Corporate Officer/Principal at DISC MEDICINE, INC.
Net worth: 972 382 $ as of 2024-04-29
Profile
Pamela Stephenson is currently the Chief Commercial Officer at Disc Medicine, Inc. Her former positions include being an Independent Director at Zynerba Pharmaceuticals, Inc. from 2019 to 2023, and Vice President-Global Market Access & Value at Vertex Pharmaceuticals, Inc. from 2008 to 2019.
She also served as the Chief Commercial Officer at Albireo Pharma, Inc. Ms. Stephenson received her undergraduate degree from Brown University and her graduate degree from Boston University School of Public Health.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
DISC MEDICINE, INC.
0.15% | 2024-02-25 | 36,666 ( 0.15% ) | 972 382 $ | 2024-04-29 |
Pamela Stephenson active positions
| Companies | Position | Start |
|---|---|---|
| DISC MEDICINE, INC. | Corporate Officer/Principal | 2024-02-25 |
Former positions of Pamela Stephenson
| Companies | Position | End |
|---|---|---|
| ZYNERBA PHARMACEUTICALS, INC. | Director/Board Member | 2023-10-09 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 2019-02-28 |
| ALBIREO PHARMA, INC. | Corporate Officer/Principal | - |
Training of Pamela Stephenson
| Brown University | Undergraduate Degree |
| Boston University School of Public Health | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ZYNERBA PHARMACEUTICALS, INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| DISC MEDICINE, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Pamela Stephenson